169 related articles for article (PubMed ID: 30929420)
1. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer.
Lee T; Christov PP; Shaw S; Tarr JC; Zhao B; Veerasamy N; Jeon KO; Mills JJ; Bian Z; Sensintaffar JL; Arnold AL; Fogarty SA; Perry E; Ramsey HE; Cook RS; Hollingshead M; Davis Millin M; Lee KM; Koss B; Budhraja A; Opferman JT; Kim K; Arteaga CL; Moore WJ; Olejniczak ET; Savona MR; Fesik SW
J Med Chem; 2019 Apr; 62(8):3971-3988. PubMed ID: 30929420
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent.
Lu X; Liu YC; Orvig C; Liang H; Chen ZF
J Med Chem; 2020 Sep; 63(17):9154-9167. PubMed ID: 32794745
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
Tron AE; Belmonte MA; Adam A; Aquila BM; Boise LH; Chiarparin E; Cidado J; Embrey KJ; Gangl E; Gibbons FD; Gregory GP; Hargreaves D; Hendricks JA; Johannes JW; Johnstone RW; Kazmirski SL; Kettle JG; Lamb ML; Matulis SM; Nooka AK; Packer MJ; Peng B; Rawlins PB; Robbins DW; Schuller AG; Su N; Yang W; Ye Q; Zheng X; Secrist JP; Clark EA; Wilson DM; Fawell SE; Hird AW
Nat Commun; 2018 Dec; 9(1):5341. PubMed ID: 30559424
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
Wan Y; Dai N; Tang Z; Fang H
Eur J Med Chem; 2018 Feb; 146():471-482. PubMed ID: 29407973
[TBL] [Abstract][Full Text] [Related]
5. Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells.
Doi K; Gowda K; Liu Q; Lin JM; Sung SS; Dower C; Claxton D; Loughran TP; Amin S; Wang HG
Cancer Biol Ther; 2014; 15(12):1688-99. PubMed ID: 25535900
[TBL] [Abstract][Full Text] [Related]
6. Identification of Small-Molecule Inhibitors of the Antiapoptotic Protein Myeloid Cell Leukaemia-1 (Mcl-1).
Beekman AM; O'Connell MA; Howell LA
ChemMedChem; 2016 Apr; 11(8):840-4. PubMed ID: 26616140
[TBL] [Abstract][Full Text] [Related]
7. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors.
Lee T; Bian Z; Zhao B; Hogdal LJ; Sensintaffar JL; Goodwin CM; Belmar J; Shaw S; Tarr JC; Veerasamy N; Matulis SM; Koss B; Fischer MA; Arnold AL; Camper DV; Browning CF; Rossanese OW; Budhraja A; Opferman J; Boise LH; Savona MR; Letai A; Olejniczak ET; Fesik SW
FEBS Lett; 2017 Jan; 591(1):240-251. PubMed ID: 27878989
[TBL] [Abstract][Full Text] [Related]
8. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
Leverson JD; Zhang H; Chen J; Tahir SK; Phillips DC; Xue J; Nimmer P; Jin S; Smith M; Xiao Y; Kovar P; Tanaka A; Bruncko M; Sheppard GS; Wang L; Gierke S; Kategaya L; Anderson DJ; Wong C; Eastham-Anderson J; Ludlam MJ; Sampath D; Fairbrother WJ; Wertz I; Rosenberg SH; Tse C; Elmore SW; Souers AJ
Cell Death Dis; 2015 Jan; 6(1):e1590. PubMed ID: 25590800
[TBL] [Abstract][Full Text] [Related]
9. Structure-Based Optimization of 3-Phenyl-
Li Y; Fan W; Gong Q; Tian J; Zhou M; Li Q; Uwituze LB; Zhang Z; Hong R; Wang R
J Med Chem; 2021 Jul; 64(14):10260-10285. PubMed ID: 34228434
[TBL] [Abstract][Full Text] [Related]
10. Mcl-1 as a "barrier" in cancer treatment: Can we target it now?
Pervushin NV; Senichkin VV; Zhivotovsky B; Kopeina GS
Int Rev Cell Mol Biol; 2020; 351():23-55. PubMed ID: 32247581
[TBL] [Abstract][Full Text] [Related]
11. Optimization of Potent and Selective Tricyclic Indole Diazepinone Myeloid Cell Leukemia-1 Inhibitors Using Structure-Based Design.
Shaw S; Bian Z; Zhao B; Tarr JC; Veerasamy N; Jeon KO; Belmar J; Arnold AL; Fogarty SA; Perry E; Sensintaffar JL; Camper DV; Rossanese OW; Lee T; Olejniczak ET; Fesik SW
J Med Chem; 2018 Mar; 61(6):2410-2421. PubMed ID: 29323899
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 3,5-Dimethyl-4-Sulfonyl-1
Zhu PJ; Yu ZZ; Lv YF; Zhao JL; Tong YY; You QD; Jiang ZY
J Med Chem; 2021 Aug; 64(15):11330-11353. PubMed ID: 34342996
[TBL] [Abstract][Full Text] [Related]
13. Discovery and in Vivo Evaluation of Macrocyclic Mcl-1 Inhibitors Featuring an α-Hydroxy Phenylacetic Acid Pharmacophore or Bioisostere.
Rescourio G; Gonzalez AZ; Jabri S; Belmontes B; Moody G; Whittington D; Huang X; Caenepeel S; Cardozo M; Cheng AC; Chow D; Dou H; Jones A; Kelly RC; Li Y; Lizarzaburu M; Lo MC; Mallari R; Meleza C; Rew Y; Simonovich S; Sun D; Turcotte S; Yan X; Wong SG; Yanez E; Zancanella M; Houze J; Medina JC; Hughes PE; Brown SP
J Med Chem; 2019 Nov; 62(22):10258-10271. PubMed ID: 31736296
[TBL] [Abstract][Full Text] [Related]
14. MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents.
Bolomsky A; Vogler M; Köse MC; Heckman CA; Ehx G; Ludwig H; Caers J
J Hematol Oncol; 2020 Dec; 13(1):173. PubMed ID: 33308268
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
[TBL] [Abstract][Full Text] [Related]
16. The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak.
Cao X; Yap JL; Newell-Rogers MK; Peddaboina C; Jiang W; Papaconstantinou HT; Jupitor D; Rai A; Jung KY; Tubin RP; Yu W; Vanommeslaeghe K; Wilder PT; MacKerell AD; Fletcher S; Smythe RW
Mol Cancer; 2013 May; 12(1):42. PubMed ID: 23680104
[TBL] [Abstract][Full Text] [Related]
17. Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology.
Li K
Bioorg Med Chem Lett; 2021 Jan; 32():127717. PubMed ID: 33253879
[TBL] [Abstract][Full Text] [Related]
18. MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib.
Young AI; Law AM; Castillo L; Chong S; Cullen HD; Koehler M; Herzog S; Brummer T; Lee EF; Fairlie WD; Lucas MC; Herrmann D; Allam A; Timpson P; Watkins DN; Millar EK; O'Toole SA; Gallego-Ortega D; Ormandy CJ; Oakes SR
Breast Cancer Res; 2016 Dec; 18(1):125. PubMed ID: 27931239
[TBL] [Abstract][Full Text] [Related]
19. Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein-Protein Interaction Modulator with the Potential of Treating Hematological Malignancies.
Romanov-Michailidis F; Hsiao CC; Urner LM; Jerhaoui S; Surkyn M; Miller B; Vos A; Dominguez Blanco M; Bueters R; Vinken P; Bekkers M; Walker D; Pietrak B; Eyckmans W; Dores-Sousa JL; Joo Koo S; Lento W; Bauser M; Philippar U; Rombouts FJR
J Med Chem; 2023 May; 66(9):6122-6148. PubMed ID: 37114951
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors.
Liu L; Liu R; Yang X; Hou X; Fang H
Eur J Med Chem; 2020 Apr; 191():112142. PubMed ID: 32088497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
